• Nicolás Roberto Robles, Isis Cerezo, and Roman Hernandez-Gallego.
• 1Cardiovascular Risk Chair, University of Salamanca School of Medicine, Salamanca, Spain.
• J. Cardiovasc. Pharmacol. Ther. 2014 Jan 1; 19 (1): 14-33.

AbstractThe two major classes of drugs that target the RAS are the angiotensin-converting enzyme (ACE) inhibitors and the selective AT1 receptor blockers (ARBs). Although both of these drug classes target angiotensin II, the differences in their mechanisms of action have implications for their effects on other pathways and receptors that may have therapeutic implications. Both ACEIs and ARBs are effective antihypertensive agents that have been shown to reduce the risk of cardiovascular and renal events. Direct inhibition of renin -the most proximal aspect of the RAS -became clinically feasible from 2007 with the introduction of aliskiren. This latter drug has been shown to be efficacious for the management of hypertension. Combined therapy of direct renin-inhibitors with ACEIs or ARBs has been tested in some clinical situations as congestive HF and proteinuria with diverse results. This article tries to offer an updated review of current knowledge on the use of RAS blocking drugs in clinical settings.

23 keywords...

hide…